Wuhan Thalys Med Tech Co Ltd (603716) — Capital Reinvestment Ratio
Wuhan Thalys Med Tech Co Ltd (603716) has a Capital Reinvestment Ratio of 0.03x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥54.57 Million) in capital expenditures (CN¥1.57 Million). See Wuhan Thalys Med Tech Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Wuhan Thalys Med Tech Co Ltd Capital Reinvestment Ratio (2012–2024)
This chart tracks Wuhan Thalys Med Tech Co Ltd's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for Wuhan Thalys Med Tech Co Ltd (2012–2024)
Year-by-year Capital Reinvestment Ratio for Wuhan Thalys Med Tech Co Ltd from 2012 to 2024. For live market cap and broader valuation context, see Wuhan Thalys Med Tech Co Ltd market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.23x | CN¥99.60 Million | CN¥23.21 Million | ▼ -28.1% |
| 2023 | 0.32x | CN¥125.89 Million | CN¥40.83 Million | ▼ -83.3% |
| 2022 | 1.94x | CN¥28.12 Million | CN¥54.64 Million | ▼ -84.9% |
| 2020 | 12.84x | CN¥9.94 Million | CN¥127.70 Million | ▲ +1150.0% |
| 2019 | 1.03x | CN¥93.92 Million | CN¥96.49 Million | ▲ +17.0% |
| 2015 | 0.88x | CN¥46.11 Million | CN¥40.47 Million | ▼ -16.8% |
| 2014 | 1.06x | CN¥30.07 Million | CN¥31.73 Million | ▼ 0.0% |
| 2013 | 1.06x | CN¥32.54 Million | CN¥34.35 Million | ▼ -93.1% |
| 2012 | 15.20x | CN¥2.70 Million | CN¥41.04 Million | — |